Zobrazeno 1 - 10 of 34 pro vyhledávání: '"Michael H. Veeder"'
3
Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group
Autor: David W. Hillman, Rafael Fonseca, Thomas E. Witzig, Roscoe F. Morton, Stephen M. Ansell, David W. Brown, Michael H. Veeder, Paul A. S. Fishkin, David J. Inwards, Paul J. Kurtin
Publikováno v: Cancer. 113:108-116
BACKGROUND. The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95-80-53, patients re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931c7cd6851766dd2231f84e4801ca12
https://doi.org/10.1002/cncr.23537
Zobrazit plný text záznamu
4
Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer
Autor: Patrick A. Burch, James N. Ingle, James E. Krook, Michael W. Cannon, David W. Hillman, James A. Mailliard, Edith A. Perez, Michael H. Veeder, Kendrith M. Rowland
Publikováno v: American Journal of Clinical Oncology. 28:195-200
This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days for patients with previously treated metastatic breast cancer.Eligible p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d67a067b78b9a48dea4e9b93a50fb3f
https://doi.org/10.1097/01.coc.0000144815.54746.d0
Zobrazit plný text záznamu
5
A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932
Autor: James A. Mailliard, Tom R. Fitch, Ferdinand Addo, Edith A. Perez, Michael H. Veeder, Daniel J. Walsh, Vera J. Suman, John T. Cole, Patrick J. Flynn, James N. Ingle
Publikováno v: Oncology. 69:117-121
Objective: A phase II multi-institutional clinical trial conducted to evaluate the efficacy and tolerability of docetaxel and carboplatin as first-line therapy for women with metastatic breast cancer. Methods: Patients had histologically confirmed me
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b79a7dd8359ec9578e268b5b9723e86
https://doi.org/10.1159/000087813
Zobrazit plný text záznamu
6
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
Autor: Carl G. Kardinal, Vera J. Suman, Robert J. Dalton, Lynn C. Hartmann, Charles L. Loprinzi, James E. Krook, James A. Mailliard, Cheryl A. Conover, Michael H. Veeder, Michael N. Pollak, James N. Ingle
Publikováno v: Cancer. 85:1284-1292
BACKGROUND Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcino
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59a126af15d31af3acf425241e049cbe
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1284::aid-cncr10>3.0.co
Zobrazit plný text záznamu
8
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
Autor: Charles L. Loprinzi, James R. Egner, Michael H. Veeder, Paul J. Novotny, Susan K. Quella, Debra K. Swan, Debra L. Barton, Jeff A. Sloan, Nancy L. Vaught, Philip J. Stella, Pat Fidler
Publikováno v: Journal of Clinical Oncology. 16:495-500
PURPOSE Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a38f1ef36a781e85aaadfdd8cb6f33
https://doi.org/10.1200/jco.1998.16.2.495
Zobrazit plný text záznamu
9
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer
Autor: James A. Mailliard, Ronnie J. Kirschling, Paul L. Schaefer, Vera J. Suman, James N. Ingle, Carl G. Kardinal, Michael H. Veeder
Publikováno v: Breast Cancer Research and Treatment. 43:193-200
Based on reports of substantial antitumor efficacy of the combination of mitoxantrone (DHAD), 5-fluorouracil (FU) and leucovorin (LV), a clinical trial was performed to attempt augmentation of the dose of DHAD with filgrastim support. The doses and s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45cf0788f7a3afe2f41edb2ff139a387
https://doi.org/10.1023/a:1005749115033
Zobrazit plný text záznamu
10
The role of radiotherapy in the management of operable locally advanced breast carcinoma
Autor: Donna Neuberg, Melvyn P. Richter, John E. Olson, Kennedy W. Gilchrist, Lawrence J. Solin, Geoffrey Falkson, Kishan J. Pandya, Michael H. Veeder, Douglass C. Tormey
Publikováno v: Cancer. 79:1138-1149
BACKGROUND The purpose of this study was to test the role of radiotherapy following total mastectomy, axillary dissection, and adjuvant systemic therapy in the management of operable locally advanced breast carcinoma. METHODS After undergoing mastect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4024771e00713562972b20a68053180f
https://doi.org/10.1002/(sici)1097-0142(19970315)79:6<1138::aid-cncr12>3.0.co
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje